X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
OLP-1002 is an SCN9A antisense PNA and selectively inhibits the expression of Nav1.7 sodium channel in neuronal cells. It replicates much of the phenotype of people with a null mutation in the SCN9A gene. It is being investigated for chronic osteoarthritis.
Lead Product(s): OLP-1002
Therapeutic Area: Musculoskeletal Product Name: OLP-1002
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Details:
OLP-1002 is an SCN9A antisense PNA and selectively inhibits the expression of Nav1.7 sodium channel in neuronal cells. It replicates much of the phenotype of people with a null mutation in the SCN9A gene. It is being investigated for chronic osteoarthritis.
Lead Product(s): OLP-1002
Therapeutic Area: Musculoskeletal Product Name: OLP-1002
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2023
Details:
The collaboration will focus on editing and modifying gene expression using ASOs in disease states where the expression of genes is either altered or the sequence of the expressed genes can be altered for therapeutic benefit.
Lead Product(s): Antisense Oligonucleotide
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Vanda Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 29, 2022
Details:
OLP-1002 is an SCN9A antisense peptide nucleic acid (PNA) and selectively inhibits the expression of Nav1.7 sodium channel, and therefore expected to replicate much of the phenotype of people with SCN9A channelopathy.
Lead Product(s): OLP-1002
Therapeutic Area: Musculoskeletal Product Name: OLP-1002
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2022
Details:
OLP-1002 manifested excellent safety in a UK Phase 1 study evaluated in a total of 116 healthy volunteers. In the meantime, an exploratory Phase 1b study in Australia suggested clues to strong efficacy and long therapeutic duration in OA patients.
Lead Product(s): OLP-1002
Therapeutic Area: Neurology Product Name: OLP-1002
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
